z-logo
Premium
Classifying the intensity of pediatric cancer treatment protocols: The intensity of treatment rating scale 2.0 (ITR‐2)
Author(s) -
Werba Branlyn E.,
Hobbie Wendy,
Kazak Anne E.,
Ittenbach Richard F.,
Reilly Anne F.,
Meadows Anna T.
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21184
Subject(s) - medicine , intensity (physics) , rating scale , pediatric cancer , scale (ratio) , cancer , oncology , statistics , cartography , physics , mathematics , quantum mechanics , geography
Background To develop and validate a method of classifying the intensity of pediatric oncology treatments using four operationally defined categories of treatment intensity. Procedure An earlier version of a rating scale, the intensity of treatment rating (ITR), was revised and validated in two phases. In the Scale Construction phase, three criterion raters revised the ITR items based on consensus and item agreement data from pediatric oncologist raters (N = 15). In the Scale Validation phase, the new ITR‐2 items were validated using a second set of pediatric oncologists external to our institution (N = 12). In addition, a third group of raters (N = 16), was employed to assess inter‐rater reliabilities for 12 patients at varying levels of treatment intensities. Results Agreement between criterion ratings and the median of external raters for all 34 items on the ITR‐2 was very high (r = 0.95, range 0.71–0.91). When the ITR‐2 was used to rate 12 patient examples, the inter‐rater agreement among pediatric oncologists was also very high (median agreement between criterion‐rater pairs: r = 0.87; overall relatedness among 16 raters: r ICC  = 0.83). Conclusions The revised ITR Scale 2.0 (ITR‐2) is a valid and reliable scale for classifying the intensity of pediatric oncology treatments. Pediatr Blood Cancer 2007;48:673–677. © 2007 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here